HUTCHMED Seeks FDA Approval for Orpathys-Tagrisso Lung Cancer Treatment

• HUTCHMED submitted a US FDA application for Orpathys with Tagrisso in advanced MET-overexpressing or MET-amplified lung cancer following EGFR-TKI progression.
• Regulatory submissions in Europe and Japan are progressing as planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610252000PRIMZONEFULLFEED9852736) on October 26, 2026, and is solely responsible for the information contained therein.